Annovis Bio, Inc. 8-K

What Happened

• Annovis Bio, Inc. (ANVS) held its 2026 Annual Meeting of Stockholders virtually on June 17, 2026 and filed an 8-K reporting the results. A total of 21,705,113 shares were represented, equal to 62.65% of common stock outstanding as of the April 28, 2026 record date.
• All five director nominees were elected to one-year terms: Michael Hoffman, Maria Maccecchini, Claudine Bruck, Reid McCarthy and Mark White. Stockholders also ratified Ernst & Young LLP as the Company’s independent auditors, approved an amendment to the 2019 Equity Incentive Plan, and passed advisory (non-binding) votes on executive compensation and on holding those advisory votes every two years.

Key Details

• Shares represented at meeting: 21,705,113 (62.65% of outstanding as of April 28, 2026).
• Equity plan amendment approved: authorized shares increased from 4,000,000 to 5,500,000; annual per-person cap increased from 400,000 to 600,000 shares.
• Auditor ratification vote: For 20,634,176; Against 568,155; Abstain 502,782.
• Advisory vote on frequency: “Two years” received 5,390,514 votes (versus 2,526,008 for 1-year and 1,086,528 for 3-years); the Company will hold advisory executive-compensation votes every two years going forward.

Why It Matters

• The meeting preserves board continuity with all five nominees elected and keeps the current auditor in place, supporting continuity in corporate oversight and financial reporting.
• The approved expansion of the Equity Incentive Plan increases the pool of shares available for employee and director awards, which can affect future dilution for common shareholders.
• The advisory (non-binding) approvals — including the two-year frequency for executive pay votes — indicate shareholder support for the Company’s compensation approach and governance cadence, though they are not legally binding.